What does a high hs-CRP mean? A risk signal, not a diagnosis

A high hs-CRP means the blood carries more of a protein the liver releases when inflammation is running quietly in the background, and that pattern goes with a higher chance of heart attack or stroke, and of dying earlier. It is a risk marker rather than a diagnosis. Nothing in the number says where the inflammation is coming from.

The high-sensitivity part of the name refers to the laboratory method, which reads the low values found in people who are not obviously ill. The protein is the same one a standard CRP test measures.

Pooling 14 studies of 83,995 adults from the general population, people in the highest hs-CRP group were 103% more likely, or about twice as likely, to die of cardiovascular disease than people in the lowest group, 75% more likely to die of any cause, and 25% more likely to die of cancer [4]. The cancer link held in men, who were 26% more likely, and did not appear in women [4].

Two cut-offs recur in the research. One British dataset of 357,220 adults with no existing heart disease split them at 2 mg/L (milligrams per litre, the unit on the lab report), and 35% sat at or above that line [3]. A study of 335 pilots and air traffic controllers used 3 mg/L, and 127 of them, just under 40%, were above it [6].

Being above the line is common, and it travels with things already known to raise cardiovascular risk. Among those pilots and controllers, a raised hs-CRP was most strongly linked to:

• older age
• high blood pressure
• type 2 diabetes
• a fast resting heart rate
• a thickened heart muscle [6]

Smoking, physical inactivity and metabolic syndrome were also more common in the raised group [6]. Adding hs-CRP to the risk estimate for that group moved 25% of them into a different risk band, mostly from moderate to high [6].

Lowering the number is where the evidence splits. In 10,061 people who had already had a heart attack and whose hs-CRP was 2 mg/L or above, canakinumab, an antibody that blocks one inflammatory messenger, was tested at three doses. The middle dose lowered hs-CRP by 37 percentage points more than placebo and cut heart attacks, strokes and cardiovascular deaths from 4.50 to 3.86 per 100 people a year, about 15% less likely [15]. Deaths from any cause did not fall, and fatal infections were more common on the drug [15].

The second trial went the other way. In 7,062 people after a heart attack, colchicine, an older anti-inflammatory drug, lowered hs-CRP by 1.28 mg/L more than placebo and changed nothing measurable: a further cardiovascular event hit 9.1% of the treated group and 9.3% of the placebo group over about three years [13]. Two other trials of colchicine had reported fewer repeat events [12], so the evidence on it is split rather than settled.

Inflammation also sits beside other risks instead of summarising them. In the British dataset, lipoprotein(a), an inherited cholesterol-carrying particle, raised the risk of heart attack and stroke by the same amount whether someone's hs-CRP was above or below 2 mg/L [3], and the pattern repeated in 34,020 people who already had heart or metabolic disease [3]. Reviews of what remains after cholesterol-lowering treatment place inflammation, lipoprotein(a) and triglyceride-rich remnant particles side by side as separate contributors [11].

CRP is probably not the thing doing the damage. It sits at the end of a chain: the immune system's inflammasome releases interleukin-1 beta, a messenger protein; that triggers interleukin-6, another messenger; and interleukin-6 instructs the liver to pour out C-reactive protein, which is what the blood test picks up [10]. The test reads the smoke rather than the fire.

The fire is in the artery wall. Cholesterol-carrying particles cross into the wall, stay there and are chemically altered, which damages the lining and draws in immune cells. Those cells release inflammatory messengers, swallow fat until they turn into foam cells, and put out enzymes that chew through the tissue holding a plaque together [7]. A plaque that comes apart is what causes a heart attack [7].

That chain is why the drug trials were built the way they were. Canakinumab blocks interleukin-1 beta, one step upstream of the liver's CRP response, and cutting events without touching cholesterol was the first direct evidence that damping inflammation on its own changes outcomes [12] [15]. The same logic explains why hs-CRP is used to decide who might benefit from treatment at all: an inflammatory reading can point statins, prescription drugs that lower cholesterol, towards people whose LDL cholesterol is not raised [12].

How much inflammation someone carries varies from patient to patient, and hs-CRP rises and falls on its own timetable in the weeks after a heart attack, which makes a single value harder to read [8].

Nearly all the prediction evidence is observational. These studies watched what happened to people who already had different hs-CRP levels rather than assigning anyone a level, so a high reading may be marking other problems instead of creating them [4].

hs-CRP is not specific to arteries either. In the occupational study it was already attached to age, blood pressure, diabetes, heart rate and heart muscle thickness [6], so one raised value on a wellness panel is not a finding about the heart.

The evidence does not stretch evenly:

• The occupational study covered 335 pilots and air traffic controllers, 99% of them men, average age 45, which is not a general population; its authors wrote that the costs and benefits of testing more widely still need assessing [6].
• Both drug trials enrolled only people who had already had a heart attack [15] [13], so neither shows what lowering hs-CRP does for a healthy person with a high number.
• The cancer signal appeared in men and not in women [4].
• The composite scores that blend hs-CRP with cholesterol or blood sugar rest on narrower evidence: one is a single-moment snapshot of 8,581 American adults [5], another depends on participants reporting their own strokes and heart disease [2].

Canakinumab and colchicine are prescription medicines given under specialist supervision, and one of them caused more fatal infections than placebo [15]. Whether any of this applies to one person is a question for a doctor holding the rest of the picture.

hs-CRP is a standard line on the blood panels longevity clinics offer, usually bundled with cholesterol, blood sugar and liver markers rather than ordered alone. A first visit generally means a health questionnaire and a blood draw, then a second appointment to go through the results. Some clinics fold the panel into a membership, others charge per test.

What comes back is most informative next to everything else on the sheet, which makes a high result a reason to read the rest of it rather than a number to chase downwards on its own. A raised hs-CRP alongside high blood pressure and type 2 diabetes sits in different company from a raised hs-CRP with every other number normal. In the study of pilots and air traffic controllers, the raised group carried those same conditions far more often than the rest [6].